Lack of follow-up of prostate-specific antigen test results.

Public Health Rep

University of Texas School of Public Health, Division of Health Promotion and Behavioral Sciences, San Antonio Regional Campus, 8550 Datapoint Dr., Ste. 200, San Antonio, TX 78229, USA.

Published: October 2009

Objectives: We obtained population estimates of the prevalence of lack of diagnostic follow-up after an abnormal prostate-specific antigen (PSA) result and assessed the role of sociodemographic, access, and risk perception factors on follow-up of abnormal tests.

Methods: We used data from the 2000 National Health Interview Survey cancer control supplement. For 3,310 men aged 40 or older with a PSA test, 463 men reported an abnormal PSA test. Outcomes were abnormal PSA and lack of diagnostic follow-up in the latter group. Covariates for logistic regression included sociodemographic variables (age, race/ethnicity, and education), access to care (health insurance and usual source), and risk of cancer (family history and perceived risk). Survey analysis procedures accounted for the complex survey design.

Results: Abnormal PSA results were associated with age, family history, and perceived risk of cancer. Approximately 15% of men with abnormal PSA tests reported no follow-up. The estimated number was 423,549 (95% confidence interval [CI] 317,755, 529,343). No follow-up was more likely in Hispanic men (odds ratio [OR] = 2.21, 95% CI 1.04, 4.70) and men without insurance (OR=6.56, 95% CI 2.02, 21.29), but less likely in men with a family history of prostate cancer or higher perceived risk of cancer.

Conclusions: Substantial numbers of men had no follow-up of abnormal PSA tests. Primary care physicians should assess continuity of care following abnormal PSA results. Data about prostate cancer screening and follow-up are needed to support clinical and policy decisions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728664PMC
http://dx.doi.org/10.1177/003335490912400514DOI Listing

Publication Analysis

Top Keywords

abnormal psa
24
follow-up abnormal
12
family history
12
perceived risk
12
prostate-specific antigen
8
lack diagnostic
8
diagnostic follow-up
8
abnormal
8
psa
8
psa test
8

Similar Publications

Background and objective Prostate cancer (PCA) is the most prevalent cancer among males. The National Institute for Health and Care Excellence (NICE) recommends referral to PCA diagnostic pathway based on two criteria: (1) abnormal digital rectal examination (DRE) and (2) elevated prostate-specific antigen (PSA). This study evaluates the diagnostic value of routine DRE in patients undergoing PCA assessment with pre-biopsy MRI.

View Article and Find Full Text PDF

() is a Gram-negative, obligate anaerobic, commensal bacterium residing in the human gut and holds therapeutic potential for ulcerative colitis (UC). Previous studies have indicated that capsular polysaccharide A (PSA) of is a crucial component for its effectiveness, possessing various biological activities such as anti-inflammatory, anti-tumor, and immune-modulating effects. We previously isolated and characterized the strain ZY-312 from the feces of a healthy breastfed infant, and extracted its PSA, named TP2.

View Article and Find Full Text PDF

Mismatch repair deficiency (MMRd) or microsatellite instability high (MSI-H) is rare in prostate cancer and more frequently observed in cases with ductal histology. MLH1 copy number loss is extremely rare in MMRd tumors. Herein, we describe a case of prostate ductal adenocarcinoma with MLH1 copy number loss, microsatellite instability high and BRCA2 mutation could derive benefit from immunotherapy plus ADT.

View Article and Find Full Text PDF

The objective of this study is to evaluate the clinical application and primary outcome of transcatheter embolization using Amplatzer™ Vascular Plug (AVP) Type 2 and Type 4 in different congenital cardiovascular malformations. This is a single-center retrospective observational cohort study. We analyzed clinical and imaging data of 36 patients retrospectively who received transcatheter embolizations of the following malformations using AVP: systemic-to-pulmonary collateral arteries (SPCA), patent ductus arteriosus (PDA), ventricular septal defects (VSD), and aberrant pulmonary sequestration arteries (PSA).

View Article and Find Full Text PDF

Aim: To evaluate the impact of different b-value combinations on synthetic diffusion-weighted imaging (sDWI) and determine the sDWI with an optimal b-value combination for prostatic cancer (PCa) diagnosis.

Material And Methods: A retrospective analysis of 68 patients with abnormal prostate-specific antigen (PSA) was conducted. The sDWI images with b value of 1500 s/mm were separately reconstructed by the following five b-value combinations: b=0, 200s/mm (sDWI); b=600, 800s/mm (sDWI); b=0, 600s/mm (sDWI); b=200, 800s/mm sDWI); b=0, 800s/mm (sDWI).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!